查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2089087

人用狂犬疫苗市場：依疫苗類型、給藥途徑、劑型、通路和最終用戶分類－2026-2032年全球市場預測

Human Rabies Vaccines Market by Vaccine Class, Route Of Administration, Formulation, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，人類狂犬病疫苗市場規模將達到 15.2 億美元，複合年成長率為 4.76%。

主要市場統計數據
基準年 2025 11億美元
預計年份：2026年 11.5億美元
預測年份 2032 15.2億美元
複合年成長率 (%) 4.76%

儘管狂犬病是最可預防的感染疾病之一，但人類狂犬病疫苗仍是一個尚未充分開發的核心市場領域。狂犬病一旦出現臨床症狀，致死率幾乎為100%。世界衛生組織建議的最新暴露後預防（PEP）方案，即使用細胞培養的狂犬病疫苗，如果能夠迅速且正確地進行，則非常有效。世界衛生組織估計，狂犬病每年導致約59,000人死亡，其中高達99%的死亡是由犬隻傳播的狂犬病引起的。

人類狂犬病疫苗的需求受多種因素驅動，包括緊急醫療服務的可近性、動物咬傷的發生率、旅客免疫接種、職業風險、國家免疫政策以及根除計畫。商業性和公共衛生部門的優先事項日益趨於一致，包括提供暴露後預防藥物、高危險群的暴露前預防、替代傳統的神經組織疫苗，以及世界衛生組織、聯合國糧農組織、世界動物衛生組織和全球狂犬病聯盟提出的「2030年零死亡」目標，即到2030年消除犬源性狂犬病造成的人類死亡。

為重組狂犬病疫苗接種體係而進行的變革性改革。

人類狂犬病疫苗接種的模式正在從被動的緊急治療轉向以預防為重點的綜合狂犬病控制方法。醫療衛生系統正在優先考慮及時進行暴露後預防（PEP）、基於風險的暴露前預防、在適當情況下進行皮內接種，並在「同一健康」框架下加強公共衛生、獸醫服務和監測部門之間的協調。

人工智慧對狂犬病疫苗的累積影響

人工智慧（AI）不再是遙遠的未來創新，而是正在成為狂犬病預防領域一股實際的力量。人工智慧驅動的咬傷監測可以幫助識別地理叢集、預測疫苗需求，並指南診所儲備暴露後預防（PEP，即潛在有效肺部引流裝置）物資。這些功能尤其重要，因為在狂犬病流行地區，疫苗和狂犬病免疫球蛋白的供應延遲仍然是導致可預防死亡的主要原因。

人類狂犬疫苗需求的關鍵區域分析

亞太地區是人類狂犬病疫苗最重要的需求中心之一。這是因為狂犬病在多個人口稠密的國家仍然很流行，而且該地區佔全球犬咬傷風險的很大一部分。印度在全球狂犬病負擔中佔相當大的比例，而中國和東南亞國家則持續投資於犬咬傷治療網路、細胞培養疫苗的供應、皮內注射暴露後預防（PEP）以及犬隻疫苗接種計劃。同時，在日本、澳洲和韓國，由於疫苗需求與旅遊醫學、職業防護和狂犬病毒防範密切相關，該地區實行更嚴格的監測和法規結構。

狂犬病疫苗策略規劃的關鍵群體分析

東協市場的特點是動物咬傷發生率高、都市化加快、基層醫療衛生網路不斷擴展，以及持續努力提升社區層面的緊急醫療服務和事後預防（PEP）服務。一些成員國已實施皮內疫苗接種政策、咬傷應對中心模式或公共採購機制，以提高疫苗可近性並減少錯失治療機會。這些措施與區域狂犬病根除計畫以及更廣泛的「同一健康」理念相一致，該理念將人類疫苗接種、動物疫苗接種和監測聯繫起來。

各國關於人類狂犬病疫苗的關鍵訊息

在美國和加拿大，能夠可靠地獲得暴露後預防藥物（PEP）、制定完善的臨床指南、為旅行者提供疫苗接種服務，並為獸醫、檢查室人員、野生動物處理人員、動物負責人和相關人員提供職業防護。儘管由於公共衛生應對體系健全，這兩個國家的人類狂犬病病例都很少見，但由於蝙蝠傳播、野生動物攜帶以及國際旅行等原因，仍然需要及時接種最新的狂犬病疫苗。墨西哥和巴西受益於當地在透過疫苗接種和監測控制犬類狂犬病方面取得的進展，但在醫療服務資源有限的地區，持續投資於快速治療、集體爆發檢測和公眾意識提升仍然至關重要。

為人類狂犬病疫苗產業的領導者提供的實用建議

產業領導者應優先考慮可靠的供應、基於證據的需求預測以及與流行地區的公共衛生系統合作。製造商和供應商可以透過提供皮內接種培訓支援、合適的包裝配置、低溫運輸解決方案以及庫存管理模式來提升自身競爭力，從而確保暴露後及時獲得疫苗，同時減少終端用戶診所的浪費。

調查方法和證據

本執行摘要基於二手研究，參考了公共衛生和監管機構的權威資料，包括世界衛生組織狂犬病指南、美國疾病控制與預防中心臨床建議、泛美衛生組織區域狂犬病最新情況、國家免疫政策、關於細胞培養狂犬病疫苗的同行評審證據，以及已發布的關於實施暴露後預防 (PEP) 和暴露前預防的資訊來源。

結論與策略展望

狂犬病雖然可以預防，但一旦出現症狀幾乎總是致命的，因此人類用狂犬病疫苗對全球公共衛生至關重要。長期醫療需求、全球根除狂犬病的目標、旅行和職業風險，以及暴露前和暴露後預防，都依賴安全、現代的細胞培養疫苗，這些因素共同支撐著疫苗的持續需求。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：人用狂犬疫苗市場：依疫苗類型分類

  • 人類二倍體細胞
  • 純化的雞胚細胞
  • 純化的Vero細胞

第8章：人用狂犬疫苗市場：依給藥途徑分類

  • 皮內注射
  • 肌肉內部

第9章：人用狂犬疫苗市場：以劑型分類

  • 液體
  • 冷凍乾燥製劑

第10章：人用狂犬疫苗市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章：人用狂犬疫苗市場：依最終用戶分類

  • 診所
  • 醫院
  • 研究機構

第12章 人類狂犬病疫苗市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 人類狂犬病疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 人類狂犬病疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Bavarian Nordic A/S
  • Bharat Biotech International Limited
  • Bio-Med Pvt. Ltd.
  • Cadila Healthcare Ltd.
  • Chengda Biotechnology Co., Ltd.
  • GlaxoSmithKline plc
  • Hualan Biological Engineering Inc.
  • Indian Immunologicals Limited
  • Novartis AG
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Shenzhen Kangtai Biological Products Co., Ltd.
  • Sinovac Biotech Ltd.
  • Valneva SE
Product Code: MRR-710B1F0AC439

The Human Rabies Vaccines Market is projected to grow by USD 1.52 billion at a CAGR of 4.76% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.10 billion
Estimated Year [2026] USD 1.15 billion
Forecast Year [2032] USD 1.52 billion
CAGR (%) 4.76%

Human rabies vaccines sit at the center of one of the most preventable yet persistently underaddressed infectious disease markets. Rabies is almost universally fatal once clinical symptoms appear, while modern post-exposure prophylaxis (PEP) using WHO-recommended cell-culture rabies vaccines is highly effective when administered promptly and correctly. The World Health Organization (WHO) estimates that rabies causes about 59,000 human deaths annually, with dog-mediated rabies responsible for up to 99% of human cases.

Demand for human rabies vaccines is shaped by emergency care access, animal-bite incidence, traveler vaccination, occupational risk, national immunization policies, and elimination programs. Commercial and public health priorities are increasingly aligned around PEP access, pre-exposure prophylaxis for high-risk groups, replacement of obsolete nerve-tissue vaccines, and the WHO, FAO, WOAH, and GARC "Zero by 30" goal to end human deaths from dog-mediated rabies by 2030.

Transformative Shifts Reshaping Rabies Vaccination

The human rabies vaccines landscape is shifting from reactive emergency treatment toward prevention-focused, integrated rabies control. Health systems are prioritizing timely PEP, risk-based pre-exposure prophylaxis, intradermal regimens where appropriate, and closer coordination between human health, veterinary services, and surveillance under the One Health framework.

Product modernization is another defining shift. Purified chick embryo cell vaccine, purified Vero cell rabies vaccine, and human diploid cell vaccine have become preferred options over obsolete nerve-tissue products due to stronger safety, potency, and immunogenicity profiles. Procurement agencies are also focusing on cold-chain resilience, dose-sparing schedules endorsed in WHO guidance, reliable rabies immunoglobulin access for severe exposures, and uninterrupted supply during outbreaks, natural disasters, and periods of increased animal-bite reporting.

Cumulative Impact of Artificial Intelligence on Rabies Vaccines

Artificial intelligence is becoming a practical enabler in rabies prevention rather than a distant innovation. AI-supported bite surveillance can help identify geographic clusters, predict vaccine demand, and guide where clinics should maintain PEP inventory. These capabilities are especially valuable because delayed access to rabies vaccine and rabies immunoglobulin remains a major contributor to preventable deaths in endemic settings.

AI is also strengthening manufacturing, quality systems, and pharmacovigilance for biologics. Predictive maintenance, digital batch analytics, anomaly detection, and automated deviation review can improve production continuity and quality oversight. In public health operations, AI-enabled forecasting can help reduce stockouts, optimize cold-chain routing, prioritize high-risk districts, and support targeted community education on wound washing, urgent PEP initiation, and completion of vaccination schedules.

Key Regional Insights Across Human Rabies Vaccine Demand

Asia-Pacific represents one of the most important demand centers for human rabies vaccines because rabies remains endemic across several densely populated countries, and the region accounts for a large portion of global dog-bite exposure risk. India carries a substantial share of the global rabies burden, while China and Southeast Asian countries continue to invest in bite-treatment networks, cell-culture vaccine access, intradermal PEP delivery, and dog vaccination programs. Japan, Australia, and South Korea operate under stronger surveillance and regulatory frameworks, with demand more closely tied to travel medicine, occupational protection, and lyssavirus preparedness.

North America is a mature, protocol-driven region characterized by strong regulatory oversight, ready access to emergency PEP, traveler vaccination, and pre-exposure prophylaxis for veterinarians, laboratory personnel, wildlife professionals, and other high-risk workers. Europe similarly benefits from advanced travel medicine infrastructure, pharmacovigilance systems, and consistent vaccine quality standards, although imported exposures, wildlife rabies monitoring, and professional risk groups sustain ongoing demand. Latin America has demonstrated measurable progress through coordinated dog vaccination, surveillance, and access programs, with regional public health authorities documenting major reductions in human dog-mediated rabies deaths over recent decades.

The Middle East and Africa present contrasting dynamics. Gulf countries emphasize vaccine import security, traveler health, pilgrimage-related preparedness, and emergency response capacity, while parts of the wider Middle East require strengthened surveillance and cross-border animal health coordination. Africa carries a substantial share of global rabies mortality, particularly in settings where access to timely PEP, rabies immunoglobulin, diagnostics, and cold-chain infrastructure is constrained. Across all regions, the strongest public health impact comes from linking human rabies vaccination with dog vaccination, bite reporting, community awareness, and One Health surveillance.

Key Group Insights for Strategic Rabies Vaccine Planning

ASEAN markets are shaped by high animal-bite volumes, urbanization, expanding primary healthcare networks, and ongoing efforts to strengthen PEP availability in emergency and community-level settings. Several member states have implemented intradermal vaccination policies, bite-center models, or public procurement mechanisms to improve affordability and reduce missed treatment opportunities. These initiatives align with regional rabies elimination plans and the broader One Health approach connecting human vaccination, animal vaccination, and surveillance.

The GCC prioritizes secure vaccine procurement, traveler health, pilgrimage preparedness, and emergency response capacity, reflecting its high international mobility and reliance on reliable biologics supply chains. The European Union emphasizes harmonized regulatory standards, pharmacovigilance, travel medicine guidance, and coordinated infectious disease monitoring, supporting consistent access to modern cell-culture rabies vaccines. BRICS countries are strategically important because they combine large populations, domestic biologics capacity, endemic-risk management needs, and public health investments in PEP infrastructure. G7 and NATO markets are generally lower-burden but remain influential through vaccine innovation, global health funding, military and defense-related occupational vaccination, travel medicine systems, and outbreak-response capabilities.

Key Country Insights in Human Rabies Vaccines

The United States and Canada maintain robust PEP access, established clinical guidance, travel vaccination services, and occupational protection for veterinarians, laboratory workers, wildlife handlers, animal-control personnel, and military personnel. In both countries, human rabies is rare due to strong public health response systems, but bat-associated exposures, wildlife reservoirs, and international travel sustain the need for modern rabies vaccines. Mexico and Brazil benefit from regional progress in dog-mediated rabies control through vaccination and surveillance, while continued investment in rapid treatment access, outbreak detection, and public awareness remains essential in underserved areas.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are primarily driven by travel health, imported exposure risk, occupational vaccination, and public health preparedness, with clinical practice supported by national immunization guidance and pharmacovigilance systems. Russia's large geography, wildlife reservoirs, and cross-regional exposure risks create continued demand for localized readiness, vaccine availability, and surveillance coordination. Across the European setting, demand remains closely linked to risk-based pre-exposure vaccination, prompt PEP, and preparedness for exposures acquired abroad.

China and India are high-priority countries due to population scale, animal-bite incidence, urban-rural access gaps, and ongoing modernization of PEP delivery. India remains central to global rabies prevention efforts because of its disease burden and the importance of expanding timely access to cell-culture vaccines, rabies immunoglobulin for severe exposures, and dog vaccination coverage. China continues to improve rabies control through vaccination access, surveillance, and public health education. Japan, Australia, and South Korea maintain strong regulatory systems and traveler-focused demand, with Australia additionally managing Australian bat lyssavirus exposure risk and emphasizing prompt clinical evaluation after bat contact.

Actionable Recommendations for Human Rabies Vaccine Leaders

Industry leaders should prioritize dependable supply, evidence-based demand forecasting, and partnerships with public health systems in endemic markets. Manufacturers and suppliers can improve competitiveness by supporting intradermal regimen training, appropriate pack configurations, cold-chain solutions, and inventory models that reduce wastage at peripheral clinics while ensuring timely access after exposure.

Strategic investment should also extend beyond the vaccine vial. Organizations that collaborate on bite surveillance, health worker education, pharmacovigilance, rabies immunoglobulin access, and One Health programs can strengthen market access while contributing to elimination goals. In mature markets, differentiation should focus on regulatory reliability, travel clinic partnerships, occupational risk programs, digital inventory planning, and resilient supply arrangements for emergency preparedness.

Research Methodology and Evidence Base

This executive summary is built on secondary research from authoritative public health and regulatory sources, including WHO rabies guidance, CDC clinical recommendations, PAHO regional rabies updates, national immunization policies, peer-reviewed evidence on cell-culture rabies vaccines, and published guidance on PEP and pre-exposure prophylaxis delivery.

The analysis integrates epidemiology, product standards, vaccination schedules, procurement dynamics, cold-chain requirements, regional health-system capacity, travel medicine guidance, and One Health policy direction. Insights were triangulated across disease-burden data, national rabies-control strategies, biologics regulatory standards, surveillance evidence, and public health implementation indicators to identify demand drivers, access barriers, technology shifts, and strategic opportunities without relying on market sizing or forecasting.

Conclusion and Strategic Outlook

Human rabies vaccines remain indispensable to global health because rabies is preventable but almost always fatal after symptom onset. Sustained demand is supported by durable medical necessity, global elimination targets, travel and occupational risk, and continued reliance on safe, modern cell-culture vaccines for both post-exposure and pre-exposure protection.

The strongest opportunities will emerge where manufacturers, governments, and health systems connect reliable PEP supply with bite surveillance, community education, dog vaccination, rabies immunoglobulin access, and AI-enabled logistics. Stakeholders that align commercial strategy with verified public health needs will be best positioned to support the global transition from rabies treatment access to rabies death prevention.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Human Rabies Vaccines Market, by Vaccine Class

  • 7.1. Human Diploid Cell
  • 7.2. Purified Chick Embryo Cell
  • 7.3. Purified Vero Cell

8. Human Rabies Vaccines Market, by Route Of Administration

  • 8.1. Intradermal
  • 8.2. Intramuscular

9. Human Rabies Vaccines Market, by Formulation

  • 9.1. Liquid
  • 9.2. Lyophilized

10. Human Rabies Vaccines Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Online Pharmacies
  • 10.3. Retail Pharmacies

11. Human Rabies Vaccines Market, by End User

  • 11.1. Clinics
  • 11.2. Hospitals
  • 11.3. Research Institutes

12. Human Rabies Vaccines Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Human Rabies Vaccines Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Human Rabies Vaccines Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Bavarian Nordic A/S
  • 16.2. Bharat Biotech International Limited
  • 16.3. Bio-Med Pvt. Ltd.
  • 16.4. Cadila Healthcare Ltd.
  • 16.5. Chengda Biotechnology Co., Ltd.
  • 16.6. GlaxoSmithKline plc
  • 16.7. Hualan Biological Engineering Inc.
  • 16.8. Indian Immunologicals Limited
  • 16.9. Novartis AG
  • 16.10. Sanofi SA
  • 16.11. Serum Institute of India Pvt. Ltd.
  • 16.12. Shenzhen Kangtai Biological Products Co., Ltd.
  • 16.13. Sinovac Biotech Ltd.
  • 16.14. Valneva SE

LIST OF FIGURES

  • FIGURE 1. GLOBAL HUMAN RABIES VACCINES MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL HUMAN RABIES VACCINES MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL HUMAN RABIES VACCINES MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL HUMAN RABIES VACCINES MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN RABIES VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL HUMAN RABIES VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HUMAN DIPLOID CELL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN DIPLOID CELL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN DIPLOID CELL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PURIFIED CHICK EMBRYO CELL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PURIFIED CHICK EMBRYO CELL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PURIFIED CHICK EMBRYO CELL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PURIFIED VERO CELL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PURIFIED VERO CELL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PURIFIED VERO CELL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INTRADERMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INTRADERMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INTRADERMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LIQUID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LIQUID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LIQUID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LYOPHILIZED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LYOPHILIZED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LYOPHILIZED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. MIDDLE EAST HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 72. MIDDLE EAST HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 73. MIDDLE EAST HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 74. MIDDLE EAST HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 75. MIDDLE EAST HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. MIDDLE EAST HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. AFRICA HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 78. AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 79. AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 80. AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 81. AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. ASEAN HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 85. ASEAN HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 86. ASEAN HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. ASEAN HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 88. ASEAN HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. ASEAN HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. GCC HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 91. GCC HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 92. GCC HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. GCC HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 94. GCC HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. GCC HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPEAN UNION HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPEAN UNION HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPEAN UNION HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPEAN UNION HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPEAN UNION HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPEAN UNION HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. BRICS HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 103. BRICS HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 104. BRICS HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. BRICS HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 106. BRICS HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. BRICS HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. G7 HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 109. G7 HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 110. G7 HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. G7 HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 112. G7 HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. G7 HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. NATO HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 115. NATO HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 116. NATO HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. NATO HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 118. NATO HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. NATO HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 122. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 123. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 125. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. CANADA HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 128. CANADA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 129. CANADA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. CANADA HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 131. CANADA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. CANADA HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. MEXICO HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. MEXICO HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 135. MEXICO HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. MEXICO HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 137. MEXICO HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. MEXICO HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. BRAZIL HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. BRAZIL HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 141. BRAZIL HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. BRAZIL HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 143. BRAZIL HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. BRAZIL HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED KINGDOM HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED KINGDOM HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED KINGDOM HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED KINGDOM HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED KINGDOM HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED KINGDOM HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. GERMANY HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. GERMANY HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 153. GERMANY HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. GERMANY HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 155. GERMANY HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. GERMANY HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. FRANCE HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. FRANCE HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 159. FRANCE HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. FRANCE HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 161. FRANCE HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. FRANCE HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. RUSSIA HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. RUSSIA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 165. RUSSIA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. RUSSIA HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 167. RUSSIA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. RUSSIA HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. ITALY HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. ITALY HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 171. ITALY HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. ITALY HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 173. ITALY HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. ITALY HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. SPAIN HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. SPAIN HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 177. SPAIN HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. SPAIN HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 179. SPAIN HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. SPAIN HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. INDIA HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. INDIA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 189. INDIA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. INDIA HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 191. INDIA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. INDIA HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. JAPAN HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. JAPAN HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 195. JAPAN HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. JAPAN HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 197. JAPAN HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. JAPAN HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. AUSTRALIA HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. AUSTRALIA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 201. AUSTRALIA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. AUSTRALIA HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 203. AUSTRALIA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. AUSTRALIA HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. SOUTH KOREA HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. SOUTH KOREA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 207. SOUTH KOREA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. SOUTH KOREA HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 209. SOUTH KOREA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. SOUTH KOREA HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)